```html

Kernicterus in Adults

What is Kernicterus (adult)?

Kernicterus is a rare, severe form of bilirubin‑induced brain injury that most often occurs in newborns. In adults, the condition is exceedingly uncommon, but it can develop when extremely high levels of unconjugated (indirect) bilirubin cross the blood‑brain barrier and deposit in the basal ganglia, brainstem nuclei, and cerebellum. The result is a reversible or permanent neurological syndrome that may present with movement disorders, hearing loss, and cognitive impairment.

The adult form shares the same pathophysiology as neonatal kernicterus—bilirubin neurotoxicity—but the underlying risk factors differ. Because the adult brain is more mature and the blood‑brain barrier is typically more robust, bilirubin concentrations must be markedly higher (often >30 mg/dL) or the barrier must be compromised for kernicterus to develop.

Common Causes

In adults, kernicterus is usually a complication of a pre‑existing disorder that dramatically raises unconjugated bilirubin. The most frequent precipitants include:

• Hemolytic anemia – e.g., sickle cell disease, autoimmune hemolysis, hereditary spherocytosis.
• Crigler‑Najjar syndrome type I – a rare genetic deficiency of UDP‑glucuronosyltransferase.
• Gilbert’s syndrome (severe exacerbation) – normally mild, but can become critical when combined with fasting or drugs.
• Severe liver failure – acute hepatitis, alcoholic cirrhosis, or drug‑induced hepatic injury that impairs bilirubin conjugation.
• Drug‑induced enzyme inhibition – medications such as high‑dose ibuprofen, sulfonamides, or certain antiretrovirals that block bilirubin transport.
• Post‑transfusion reactions – massive hemolysis after incompatible blood transfusion.
• Sepsis with cholestasis – Gram‑negative sepsis can impair bilirubin excretion and increase hemolysis.
• Extreme fasting or starvation – prolonged caloric deprivation raises unconjugated bilirubin via increased hemolysis of red cells.
• Genetic mutations affecting bilirubin transporters – e.g., mutations in the OATP1B1/1B3 or MRP2 genes.
• Severe hyperthyroidism (thyrotoxic crisis) – increases metabolic turnover of red cells and can precipitate hemolysis.

Associated Symptoms

The clinical picture of adult kernicterus is a combination of systemic jaundice and neurologic deficits. Commonly reported findings include:

• Profound yellow discoloration of the skin and sclera (total bilirubin often >30 mg/dL).
• Acute encephalopathy – confusion, lethargy, or coma.
• Extrapyramidal signs – rigidity, tremor, or dystonia (often described as “chorea‑athetosis”).
• Auditory dysfunction – high‑frequency hearing loss that may be sudden.
• Ataxia or unsteady gait due to cerebellar involvement.
• Seizures – focal or generalized, especially when bilirubin levels climb rapidly.
• Oscillopsia or visual disturbances (rare, due to brainstem involvement).
• Psychiatric changes – agitation, irritability, or even psychosis.

When to See a Doctor

Kernicterus is a medical emergency. Seek immediate medical attention if you notice any of the following while you have known jaundice or a condition that raises bilirubin:

• Rapid worsening of yellow skin or eye discoloration.
• New or worsening confusion, drowsiness, or difficulty staying awake.
• Sudden loss of coordination, stumbling, or unsteady walking.
• Unexpected muscle stiffness, tremor, or abnormal movements.
• Hearing changes, ringing in the ears, or inability to understand speech.
• Any seizure activity, even a brief “tic” that looks like a fainting spell.

Diagnosis

Because Kernicterus is rare in adults, a systematic work‑up is essential to confirm bilirubin neurotoxicity and exclude mimicking conditions (stroke, intoxication, metabolic encephalopathies).

1. Laboratory Evaluation

• Total and direct bilirubin – a markedly elevated unconjugated fraction (>25 mg/dL) is the hallmark.
• Complete blood count (CBC) with reticulocyte count – to assess hemolysis.
• Liver function panel (AST, ALT, ALP, GGT, albumin, PT/INR) – to gauge hepatic reserve.
• Serum haptoglobin, lactate dehydrogenase (LDH) – hemolysis markers.
• Genetic testing if Crigler‑Najjar, Gilbert, or transporter defects are suspected.

2. Neuroimaging

• Magnetic Resonance Imaging (MRI) – T1‑weighted images often show hyperintensity in the basal ganglia, cerebellar dentate nuclei, and brainstem, consistent with bilirubin deposition.
• CT scan is less sensitive but may be used emergently to rule out hemorrhage.

3. Neurophysiological Tests

• Electroencephalogram (EEG) – helps differentiate seizure activity from metabolic encephalopathy.
• Audiometry – baseline and follow‑up hearing evaluations because bilirubin toxicity can be irreversible.

4. Clinical Scoring (optional)

Some centers use the “Kernicterus Severity Index” (KSI) that incorporates bilirubin level, neurological findings, and MRI changes to guide therapy intensity.

Treatment Options

Management focuses on rapidly lowering serum unconjugated bilirubin, protecting the brain, and treating the underlying cause.

1. Immediate Measures

• Phototherapy – high‑intensity blue‑light (460 nm) converts unconjugated bilirubin into water‑soluble isomers that can be excreted without conjugation. In adults, whole‑body light boxes are used, and treatment is continued until bilirubin falls below 20 mg/dL.
• Exchange transfusion – for bilirubin >40 mg/dL or when rapid reduction is required; replaces the patient’s plasma with donor blood, effectively halving the bilirubin load.
• Intravenous immunoglobulin (IVIG) – can be added if hemolysis is immune‑mediated.

2. Address the Underlying Cause

• Stop hemolytic drugs (e.g., sulfonamides, high‑dose NSAIDs).
• Treat infection or sepsis aggressively with antibiotics.
• For genetic enzyme deficiencies:
  • Crigler‑Najjar type I – liver transplantation is definitive; in the interim, phenobarbital may offer modest benefit.
  • Gilbert’s syndrome – avoid fasting, alcohol, and drugs that inhibit glucuronidation.
• Manage liver disease with standard regimens (antivirals for hepatitis, abstinence from alcohol, etc.).

3. Supportive Neurologic Care

• Seizure control with benzodiazepines or levetiracetam.
• Physical and occupational therapy for movement disorders or ataxia.
• Early audiology referral; consider hearing aids or cochlear implants if permanent loss occurs.

4. Long‑Term Monitoring

Patients who survive the acute phase require periodic assessment of:

• Neurologic function (movement, cognition, mood).
• Hearing thresholds.
• Liver and hematologic status to prevent recurrence.

Prevention Tips

Because adult kernicterus is usually secondary to another disease, prevention centers on controlling those primary conditions.

• Maintain good hydration and regular meals – prevents fasting‑induced hemolysis.
• Monitor bilirubin in known hemolytic disorders – regular labs and prompt treatment of spikes.
• Avoid drugs that impair bilirubin conjugation – discuss all over‑the‑counter and prescription meds with your physician.
• Vaccinate against hepatitis A & B – reduces the risk of chronic liver disease.
• Limit alcohol consumption – protects hepatic function.
• Screen for and treat infections early – sepsis can precipitate massive hemolysis.
• Genetic counseling for families with Crigler‑Najjar or severe Gilbert’s variants.
• Regular follow‑up for patients with liver transplant, chronic hemolysis, or enzyme deficiencies.

Emergency Warning Signs

Key Take‑aways

• Adult kernicterus is a rare but life‑threatening neurologic complication of extreme unconjugated hyperbilirubinemia.
• Recognize the “triple hit”: massive bilirubin elevation, compromised blood‑brain barrier, and an underlying disease (hemolysis, liver failure, genetic enzyme defect).
• Early intervention with phototherapy, exchange transfusion, and treatment of the root cause dramatically improves outcomes.
• Long‑term follow‑up is essential because neurologic and auditory sequelae may develop despite successful bilirubin clearance.

For more detailed information, consult reputable sources such as the Mayo Clinic, CDC, NIH, WHO, and peer‑reviewed articles in journals like The New England Journal of Medicine and Hepatology.

```